Evidence map›Paper›PMID 41162440›Full record

ArticleScientific reports2025

Meropenem dosing optimization on day 1 and steady state in critically ill patients without significant renal impairment.

Helmi Sulaiman, Muhammad Azrai Rozali, Santosh K S Adiraju, M Shahnaz Hasan, Janattul A Jamal, Xin Liu, Mohd-Basri Mat-Nor, Mohd Zulfakar Mazlan, Mohamad Irfan Othman-Jailani, Zeti Norfidiyati Salmuna and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Helmi SulaimanInfectious Diseases Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Muhammad Azrai RozaliDepartment of Pharmacy, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Malaysia.
Santosh K S AdirajuFaculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane, 4029 QLD, Australia.
M Shahnaz HasanDepartment of Anesthesiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Janattul A JamalDepartment of Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia.
Xin LiuFaculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane, 4029 QLD, Australia.
Mohd-Basri Mat-NorDepartment of Anaesthesiology and Intensive Care, Kulliyyah of Medicine, International Islamic University Malaysia (IIUM), Kuantan, Malaysia.
Mohd Zulfakar MazlanDepartment of Anesthesiology and Intensive Care, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.
Mohamad Irfan Othman-JailaniDepartment of Anesthesiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Zeti Norfidiyati SalmunaDepartment of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.
Steven C WallisFaculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane, 4029 QLD, Australia.
Jason A Roberts *Faculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane, 4029 QLD, Australia.
Mohd H Abdul-Aziz *Faculty of Medicine, University of Queensland Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane, 4029 QLD, Australia. h.abdulaziz@uq.edu.au.

Funding

Australian National Health and Medical Research Council for a Centre of Research Excellence APP2007007CRE RESPOND; Australian National Health and Medical Research Council Centre of Research Excellence APP2007007Fundamental Research Grant Scheme, Ministry of Higher Education of Malaysia FRGS16-048-0547University Malaya Private Funding PV023-2017
6 · The paper itself

Abstract

This study aimed to characterize meropenem pharmacokinetics and optimise dosing for the initial and steady state in critically ill patients. Adult patients receiving meropenem were recruited, with sampling performed on days 1 (Occasion 1) and 3 (Occasion 2) of therapy. A composite target of free drug concentrations above the minimum inhibitory concentration for the entire dosing interval (100%ƒT > MIC) and a concentration below the toxicity threshold of 45 mg/L was used. Thirty-seven patients, with a median age of 52 years, and a median estimated creatinine clearance (CLcr) and CKD Epidemiology Collaboration (CKD-EPI) estimated glomerular filtration rate (eGFR) of 68.6 mL/min and 78.2 mL/min/1.73 m

Indexed as

Anti-Bacterial AgentsMeropenemAdultAgedCritical IllnessFemaleGlomerular Filtration RateHumansMaleMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial AgentsMeropenemBeta-lactam antibioticsContinuous infusionMeropenemPharmacodynamicsPharmacokineticsSepsis

Identifiers

PMID41162440
PMCPMC12572147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.